Insider Selling: Evolus, Inc. (NASDAQ:EOLS) Director Sells 5,313 Shares of Stock

Evolus, Inc. (NASDAQ:EOLSGet Rating) Director David N. Gill sold 5,313 shares of the business’s stock in a transaction that occurred on Friday, May 13th. The stock was sold at an average price of $13.10, for a total value of $69,600.30. Following the transaction, the director now directly owns 34,568 shares in the company, valued at $452,840.80. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

NASDAQ:EOLS opened at $13.94 on Wednesday. The stock has a fifty day moving average price of $11.30 and a 200-day moving average price of $8.56. The company has a current ratio of 3.51, a quick ratio of 3.42 and a debt-to-equity ratio of 1.06. Evolus, Inc. has a fifty-two week low of $5.06 and a fifty-two week high of $14.34.

Evolus (NASDAQ:EOLSGet Rating) last released its earnings results on Tuesday, May 10th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.24. The firm had revenue of $33.90 million during the quarter, compared to the consensus estimate of $29.83 million. Evolus had a negative return on equity of 80.20% and a negative net margin of 58.28%. The company’s revenue was up 177.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.16 EPS. Analysts expect that Evolus, Inc. will post -1.26 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the company. Metropolitan Life Insurance Co NY bought a new stake in shares of Evolus during the 1st quarter valued at $26,000. Point72 Hong Kong Ltd raised its holdings in shares of Evolus by 979.7% during the 1st quarter. Point72 Hong Kong Ltd now owns 2,343 shares of the company’s stock worth $26,000 after buying an additional 2,126 shares in the last quarter. Citigroup Inc. raised its holdings in shares of Evolus by 230.9% during the 3rd quarter. Citigroup Inc. now owns 5,090 shares of the company’s stock worth $39,000 after buying an additional 3,552 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Evolus during the 1st quarter worth $60,000. Finally, BNP Paribas Arbitrage SA raised its holdings in shares of Evolus by 326.5% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 5,715 shares of the company’s stock worth $44,000 after buying an additional 4,375 shares in the last quarter. Hedge funds and other institutional investors own 36.94% of the company’s stock.

A number of research analysts recently weighed in on EOLS shares. Truist Financial raised Evolus from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a report on Thursday, January 20th. Barclays upgraded Evolus from an “underweight” rating to an “equal weight” rating and boosted their price target for the company from $8.00 to $10.00 in a research note on Thursday, May 12th. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Evolus in a research note on Friday, March 4th. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price target on shares of Evolus in a research note on Friday, March 4th. Finally, Zacks Investment Research upgraded Evolus from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a research note on Friday, May 13th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $14.50.

About Evolus (Get Rating)

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

See Also

Insider Buying and Selling by Quarter for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.